Table 1.
Major randomized phase III trials of neoadjuvant treatments with reported results for pancreatic cancer
| Study | Treatments | No. of patients | Median disease-free survival (months) | p value | Median survival (months) | p value |
|---|---|---|---|---|---|---|
| Prep-02/JSAP-05 2019 | Gemcitabine/S-1 | 182 | 14.28 | 0.028 | 36.72 | 0.015 |
| Up-front surgery | 180 | 11.28 | 26.65 | |||
| PREOPANC-1 2018 | Gemcitabine/radiation | 119 | 9.9 | 0.023 | 17.1 | 0.074 |
| Up-front surgery | 127 | 7.9 | 13.7 |
Prep Study group of preoperative therapy for pancreatic cancer, JSAP Japanese Study Group of Adjuvant Therapy for Pancreatic cancer, PREOPANC Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer